TIGIT

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

Retrieved on: 
Monday, April 8, 2024
TNF, MUC4, Alpha globulin, Disease, Macrophage, CD47, LAG3, Breast cancer, TIGIT, Poster, ADCP, TNBC, Vaccine

Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer (TNBC).  INB03 is shown to decrease T cell and macrophage immune checkpoint proteins (PD1, TIGIT, LAG3, CD47 and SIRPa) in a model immunotherapy resistant HER2+ breast cancer and decrease the metastatic potential of TNBC by downregulating cell surface markers of tumor invasion (MUC4, SNAIL and Vimectin).  The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.

Key Points: 
  • The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.
  • Decreases in T cell and macrophage immune checkpoint proteins were caused by INB03.
  • The authors speculate that these effects could avoid tumor immune evasion to anti-HER2 targeted therapies by reinvigorating the immune infiltrate.
  • Dr. Schillaci, senior author of the study, proposes INB03 is a new class of immunotherapy called a pan immune checkpoint modulator in MUC4 expressing breast cancer.

Agenus Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Oncology, OS, BOT, Colitis, Inc., Colorectal cancer, PD, RECIST, IST, Partnership, RAS, Patient, MSI, FOLFIRINOX, BMS, Melanoma, MSS, BAL, Cancer, CRC, NLM, TIGIT, Liver disease, Pharmaceutical industry

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

Key Points: 
  • Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.
  • “In 2023, Agenus made significant advances across our BOT/BAL development program.
  • $25 million milestone payment from BMS triggered by the commencement of a Phase 2 study with BMS-986442 in December 2023.
  • For the fourth quarter ended December 31, 2023, we recognized revenue of $84 million and incurred a net loss of $49 million or $0.13 per share.

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, March 6, 2024
Investment, NSCLC, Therapy, The, Cancer, Metabolism, Merck, Research, Research and development, Equilibrative nucleoside transporter 1, SITC, AACR, Koch Institute, Hub, ENT1, Immunity, Comprehension, Adenosine, Lymphocyte, Merck & Co., Administration, Patient, TIGIT, Survival, Place of birth, HNSCC, Immune system, Pharmaceutical industry

WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
  • “With the recent developments in the TIGIT field, we believe belrestotug is in an advantageous position and are excited for its future prospects.
  • We look forward to sharing updates from our Phase 2 trials focused on 1L NSCLC and 1L HNSCC in 2024.
  • On December 7, 2023, iTeos announced the appointment of David K. Lee to the Company’s Board of Directors.

Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

Retrieved on: 
Wednesday, March 6, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, CD96, Cancer, FC, Antibody, TIGIT, Inc., Vaccine

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA.

Key Points: 
  • Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA.
  • In non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade compared to conventional TIGIT antibodies.
  • BMS-986442 (AGEN1777) leverages Agenus’ proprietary Fc-engineering platform to harness novel mechanisms of action that extend beyond the capabilities of conventional anti-TIGIT therapy.
  • However, conventional TIGIT antibodies have faced limitations with monotherapy activity in clinical settings,” said Dhan Chand, Ph.D., Vice President of Research.

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

Retrieved on: 
Wednesday, February 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Cancer, PFS, PD, KIT, Toxicity, Anemia, Roche, Research and development, Security (finance), Part, Hypoxia, PD-1, Belzutifan, Safety, Income tax, Death, Access code, Administration, Exelixis, Webcast, Patient, Acceleration, TIGIT, Plasma, G&A, Pancreatic cancer, AXL, CD73, Pharmaceutical industry

Enrollment was discontinued for the Phase 3 study ARC-10 evaluating domvanalimab plus zimberelimab compared to pembrolizumab in first-line PD-L1-high NSCLC.

Key Points: 
  • Enrollment was discontinued for the Phase 3 study ARC-10 evaluating domvanalimab plus zimberelimab compared to pembrolizumab in first-line PD-L1-high NSCLC.
  • The companies also plan to initiate a Phase 2 trial to evaluate domvanalimab plus zimberelimab in a new disease setting.
  • Arcus will host a conference call and webcast today, February 21, at 2:00 PM PT / 5:00 PM ET to discuss its fourth-quarter and full-year 2023 financial results and pipeline updates.
  • To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com .

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

Retrieved on: 
Wednesday, March 6, 2024
Immunotherapy, AACR, Cytokine, Tumor microenvironment, Abstract, TIGIT, PVRIG, Biology, Compugen, Pharmaceutical industry

HOLON, Israel, March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.

Key Points: 
  • HOLON, Israel, March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.
  • "It is exciting that the progress we have made to potentially address immunotherapy resistance from diverse angles will be reflected at AACR this year," said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen.
  • Eran Ophir, Ph.D., Chief Scientific Officer at Compugen, added, "At ACCR we will present data supporting the unique biology of PVRIG suggesting its role in sensitizing tumors to other immune checkpoints TIGIT and PD-(L)1.
  • The data will be published in the online Proceedings supplement to the AACR journal Cancer Research prior to the meeting on Friday, March 22, 2024.

Gilead and Arcus Announce Amended Collaboration and Equity Investment

Retrieved on: 
Monday, January 29, 2024
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, Patient, Research, MD, Science, Partnership, Cancer, Lung cancer, NSCLC, CD73, Gilead Sciences, Safety, Gastrointestinal cancer, Doctor of Philosophy, TIGIT, Lung, Kidney cancer, Growth, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.
  • The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications.
  • Additionally, Johanna Mercier, Chief Commercial Officer at Gilead Sciences, will join the Arcus Board, bringing Gilead’s total director designees to three.
  • The amendment also includes governance enhancements enabling streamlined decision-making and reflecting the continued growth of the collaboration.

Gilead and Arcus Announce Amended Collaboration and Equity Investment

Retrieved on: 
Monday, January 29, 2024
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, Patient, Research, MD, Science, Multimedia, Partnership, Cancer, Lung cancer, NSCLC, CD73, Gilead Sciences, Safety, Gastrointestinal cancer, Doctor of Philosophy, TIGIT, Lung, Kidney cancer, Growth, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.
  • The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications.
  • Additionally, Johanna Mercier, Chief Commercial Officer at Gilead Sciences, will join the Arcus Board, bringing Gilead’s total director designees to three.
  • The amendment also includes governance enhancements enabling streamlined decision-making and reflecting the continued growth of the collaboration.

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Retrieved on: 
Monday, January 8, 2024
Compugen, PD-1, Immunotherapy, TIGIT, Cholangiocarcinoma, Pharmaceutical industry

HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled to receive a $10 million milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.

Key Points: 
  • HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled to receive a $10 million milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.
  • Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902.
  • The ARTEMIDE-Bil01 trial is expected to recruit about 750 subjects in more than 20 countries with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent.
  • "I am delighted to see the advancement of the rilvegostomig Phase 3 trial by AstraZeneca, a global leader in oncology, which has dosed the first patient triggering a $10 million milestone payment to Compugen," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen.

iTeos Announces 2024 Strategic Priorities and Anticipated Milestones

Retrieved on: 
Monday, January 8, 2024
IO, ENT1, Survival, Place of birth, PD-1, Therapy, GSK, Lymphocyte, HNSCC, Patient, TIGIT, NSCLC, Equilibrative nucleoside transporter 1, Pharmaceutical industry

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates and strategic priorities for 2024.

Key Points: 
  • and GOSSELIES, Belgium, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates and strategic priorities for 2024.
  • “Over the past twelve months, the TIGIT competitive landscape has substantially evolved, further positioning iTeos and GSK as a potential leader with our high-quality TIGIT:PD-1 doublet, belrestotug + dostarlimab.
  • The Company plans to integrate IO-001 biomarker knowledge into the development strategy of future inupadenant clinical trials.
  • The Company continues to expect its cash balance to provide runway through 2026, which includes the initiation of multiple Phase 3 registrational trials assessing the belrestotug + dostarlimab doublet.